Interim FY 2009 Funding Policy : NIDDK

Interim FY 2009 Funding Policy

The Department of Health and Human Services (HHS) is currently operating on a Continuing Resolution (CR). NIDDK has established the following funding policy until the final appropriation is enacted.

Non-competing Continuations (Type 5)

Non-competing continuations (modular and non-modular) will be funded at a level below that indicated on the most recent Notice of Award (generally up to 90% of the previously committed level). This policy does not apply to Fs, Ts, Ks, SBIR/STTRs, and R13s.

NIDDK will consider upward adjustments to this level after the final FY 2009 appropriation is enacted.

Information regarding the NIH policy can be found at this link

After the final FY 2009 appropriation is enacted information regarding NIDDK’s funding policies for this fiscal year will be posted here. What you can expect to find here at that time will include information similar to that shown below for FY 2008.

FY 2008 Funding Policy

The National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) is committed to supporting as many meritorious competing research grant applications as possible. Particular priorities are 1) enhancing the ability of new investigators to compete for support in these difficult financial times, and 2) protecting our investment in well established investigators with little or no other significant support (see NIH Guide Notice NOT-OD-08-036 [] , NIH Fiscal Policy for Grant Awards – FY 2008 ) .

To maximize our available resources, all grant awards will continue to be subject to programmatic adjustments from the National Diabetes and Digestive and Kidney Diseases (NDDK) Advisory Council approved levels. These adjustments take into consideration the overall scientific and technical merit of the grant application, the cost of the proposed research, and other resources available for related research projects.

Competing New and Renewal Research Grants

For FY 2008 NIDDK is establishing a nominal “payline” for new (Type 1) and renewal or competing continuation (Type 2) R01 applications of 17 th percentile (19 th percentile for New Investigator applications). Many if not most R01 applications requesting less than $500,000 direct cost per year and scoring better than the 17 th percentile will receive an award. However, NIDDK will exercise discretion and consider portfolio balance, programmatic importance and a number of other of factors in determining precisely which applications are awarded. In addition, as mentioned above, all grant awards will continue to be subject to programmatic adjustments from the NDDK Advisory Council approved levels. It is important to note that these funding levels are applicable for applications to be paid in FY 2008. Many applications submitted in FY 2008 will not be eligible for funding consideration until FY 2009. The funding levels for FY 2009 cannot now reliably be predicted.

NIH FY 2008 policy includes the provision of 3% escalation for future years on competing non-modular RPG awards. Applicants for modular awards are understood to have included inflation in their cost before selecting an appropriate modular total.

Non-competing Continuation Awards

Consistent with the NIH Fiscal Policy for Grant Awards - FY2008 ( NOT-OD-08-036 ) non-competing modular and non-modular grants (Type 5) of the following mechanisms - R01, R03, R18, R21, R24, R25, R33, R34, R35, R37, and P01 as well as Roadmap RPG awards - will be issued at 98% of their established committed levels. Amounts indicated for future budget periods will be adjusted as well. Non-competing U01, U19, and U24 awards will generally be issued at their established committed levels.

New Investigators

Fostering the success of new investigators establishing careers in biomedical research is a high priority of the NIDDK and NIH. The emphasis NIDDK focuses on new investigators is exhibited in the special consideration given in determining both funding priority and period of support. NIDDK routinely considers new investigator applications for payment, including those that score outside of the normal funding range. Consistent with NIH guidelines articulated in NOT-OD-036, NIDDK will maintain a number of new investigators comparable to the average of the most recent five years. In addition when possible and appropriate the full period of support recommended for funded new investigator grants will be awarded.

Duration of Grant Support

Competing awards are adjusted to achieve a 4 year average duration for research project grants. Nevertheless, applications from new investigators, initial MERIT awards, MERIT extensions, program project grants, and clinical trial grants are generally awarded for the full length of their recommended project period.

NIDDK Exploratory Research Grant (R21) Program

In response to the advice and recommendations of the NDDK Advisory Council, NIDDK refocused its R21 program in FY 2007 and this focus will remain unchanged in FY 2008. NIDDK uses R21 grants to support projects within its research mission that are:
  • Innovative, high pay-off, paradigm-shifting projects
  • Novel technology and tool development
  • Applications of existing methods, technologies, or conceptual approaches from outside biomedical science to a problem in the NIDDK mission
  • Pilot clinical trials or clinical studies

Most projects are not suitable for the R21 mechanism. In considering whether to submit an R21 application investigators should consider the following:

  • Projects of limited scope or cost that use widely accepted approaches and methods within established fields are NOT appropriate for an R21 application.
  • A proposal designed to generate preliminary data for a longer-term project in a well-established research area is NOT appropriate for an R21 application.
  • Applications from new investigators to gather preliminary data for a standard R01 are not appropriate for the R21 mechanism.
  • R21 proposals submitted by new investigators will NOT be given special priority for funding. The NIDDK believes new investigators are better served by the R01 award for which they are given special priority. Please see Resources for New Investigators.
The NIDDK will support highly risky projects if the proposed research holds promise for a major advance in biomedical research. Although preliminary data are not required, the applicant should provide evidence of his/her ability to carry out the proposed research project. The success rate of NIDDK R21 applications in the past has been highly variable and differs from the success rate for obtaining R01 awards.

Potential applicants are strongly advised to discuss a prospective proposal with a member of NIDDK Program Staff in order to determine whether it is appropriate to submit as an R21 application.

Program Project (P01) Grant Applications and Applications with budgets greater than $500K

NIDDK has adopted a more stringent funding practice for awarding program project (P01) grants and investigator-initiated grant applications with budgets of $500,000 direct costs in any one year. Prior approval is required before submitting an application for review that requests $500,000 or more in direct costs in any one year. The request to submit such applications must be received at least 6 weeks prior to the proposed submission date. Prior approval is required for renewal and revised applications as well as new applications. Please consult with the appropriate NIDDK program staff and visit the following site for information on research areas supported by NIDDK:

New (Type 1) program project (P01) applications may request a maximum of $5 million in direct costs over five years, exclusive of the subcontract Facilities & Administrative (F&A) costs. Renewal (competing continuation [Type 2]) program project applications may request up to $6.25 million in direct costs over five years, exclusive of Facilities and Administrative (F&A) costs associated with the subcontract(s). In addition to the caps on the amount requested, P01 awards are subject to administrative adjustment from the Advisory Council approved levels. Additional information regarding the P01 applications and their receipt dates can be found:

Bridge Support

In cases where a competing renewal application falls near but beyond the nominal payline, NIDDK will continue to consider interim support on a case-by-case basis and provide limited, support in selected cases. The goal is to preserve essential research resources pending the re-review of a revised application. NIDDK can choose to award a one- or two-year R56 grant to an R01 application scored outside the payline. These provide support for an investigator to collect preliminary data in order to submit an improved revised R01 application. In addition to NIDDK's efforts along these lines, NIH will continue to take specific steps using NIH Director's Bridge Awards (see NIH Guide Notice NOT-OD-08-037 Announcing the FY 2008 NIH Director's Bridge Awards ” ) to buttress investigators whose R01 applications receive review scores near the Institute or Center (IC) nominal payline and who have limited additional support. Note that applicants may not apply for a NDBA and they may not nominate themselves .

Page last updated: October 22, 2008

General inquiries may be addressed to: Office of Communications & Public Liaison
Building 31. Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560
For information about NIDDK programs: 301.496.3583

The National Institutes of Health   Department of Health and Human Services is the U.S. government's official web portal to all federal, state, and local government web resources and services.  HONcode Seal - Link to the Health on the Net Foundation